Form 4: CytomX Therapeutics SVP, Chief Scientific Officer, Marcia Belvin, Reports Acquisition of Stock Options and Restricted Stock Units

Marcia Belvin, SVP, Chief Scientific Officer of CytomX Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on February 4, 2025.

Summary

• On February 4, 2025, Marcia Belvin, the SVP, Chief Scientific Officer of CytomX Therapeutics, acquired 30,000 RSUs that vest annually starting March 15, 2026.
• She also acquired 57,500 RSUs that vest annually starting March 15, 2026.
• Belvin acquired options to purchase 140,000 shares of common stock at an exercise price of $0.864, vesting monthly from February 4, 2025, and expiring on February 3, 2035.
• Additionally, she acquired options to purchase 115,000 shares of common stock at an exercise price of $0.864, vesting monthly from February 4, 2025, and expiring on February 3, 2035.
• Following these transactions, Belvin beneficially owns 263,148 shares of common stock (including 196,666 RSUs), 140,000 stock options and 115,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, suggesting confidence in the company's future, but doesn't contain any groundbreaking news.

Positives

• The acquisition of RSUs and stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the RSUs and stock options suggest a multi-year commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of RSUs and stock options is a common practice to incentivize and retain key personnel in the biotechnology industry.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotech industry, used to align executive incentives with shareholder value.
• Vesting schedules, like the monthly vesting described, are common to ensure continued service and commitment from the executive.
• The exercise price of $0.864 for the stock options would need to be compared to the market price of CTMX at the time of the grant to assess its competitiveness.

Stakeholder Impact

• Shareholders may view the grant of RSUs and stock options as a positive sign, aligning executive interests with long-term company performance.
• Employees may see this as a positive sign of company health and stability.

Key Dates

Keywords

CytomX Therapeutics, Marcia Belvin, stock options, RSUs, Form 4, insider trading